FDA General Wellness Policy: What Non-Invasive Sensing Products Must Meet to Remain Low Risk

As wearable and software-enabled technologies increasingly estimate physiological parameters such as oxygen saturation, blood pressure, and heart rate variability, regulatory classification has become a critical design consideration. The FDA’s General Wellness: Policy for Low Risk Devices clarifies when products using non-invasive sensing—such as optical sensing—may be considered general wellness products rather than regulated medical devices. 

For developers conducting a clinical research study, understanding these boundaries early can help reduce regulatory uncertainty, limit CRO risk mitigation challenges, and prevent downstream FDA submission delays. 

When the FDA May Consider a Product “General Wellness” 

According to the FDA, certain products that estimate or infer physiological parameters may qualify as general wellness products only when their outputs are intended exclusively for wellness use and specific conditions are met. 

Key Criteria for General Wellness Classification 

To remain within the general wellness category, products must: 

• Be non-invasive and not implanted, aligning with low-risk device expectations 

• Avoid technologies or interventions that could pose safety risks without regulatory controls 

• Exclude any intent related to diagnosis, cure, mitigation, prevention, or treatment of a disease or condition 

• Not serve as a substitute for an FDA-authorized, cleared, or approved device 

• Avoid outputs that prompt or guide specific clinical action or medical management 

• Refrain from displaying values that mimic clinically used metrics unless those values are appropriately validated through manufacturer testing or peer-reviewed clinical literature 

• 
  

This final point is especially relevant for technologies associated with pulse oximetry testing, where numerical outputs can closely resemble clinically interpreted SpO₂ values. 

Implications for Physiological Monitoring and Wearable Validation 

For developers working on pulse oximetry studies, blood pressure estimation, or app validation in trials, the FDA’s position highlights a clear regulatory line: once a product presents data that resembles clinical values without appropriate validation, it may no longer be considered low risk. 

This is where structured medical device validation becomes essential. Studies conducted in a qualified pulse oximetry studies lab or hypoxia lab, including controlled desaturation protocols, help ensure that outputs are scientifically justified and regulator-ready when claims extend beyond general wellness. 

Why Early Protocol Alignment Matters 

Misalignment between product claims, output design, and regulatory intent can introduce avoidable risk. Early clinical trial protocol development and Independent Review Board (IRB) oversight help ensure that validation activities support long-term FDA clinical trial strategy.  Maintaining GCP compliance, ISO 14155 alignment, and CRO transparency is critical, even when a product initially targets the general wellness category. 

Key Takeaway for Device Developers 

The FDA’s general wellness policy does not eliminate the need for rigorous validation, it clarifies when that validation becomes necessary. As physiological sensing technologies mature, developers must carefully assess whether their outputs, claims, and numerical values remain consistent with wellness intent or signal the need for regulatory-grade evidence supporting use as a medical device. 

Conclusion: Designing for Wellness Without Regulatory Surprises 

General wellness classification offers flexibility, but only when product design, outputs, and validation strategy remain tightly aligned with FDA expectations. For organizations developing non-invasive sensing technologies, proactive protocol optimization and early regulatory thinking can prevent costly pivots later. 

PRL delivers regulator-ready clinical endpoints, inclusive participant recruitment using the Monk scale, controlled desaturation studies for pulse oximetry, and ISO-aligned blood pressure verification studies so developers can substantiate performance with confidence, whether for wellness positioning today or FDA and CE mark pathways tomorrow. Contact us today!

*See Disclaimer regarding AI-generated content